Sanofi

Sanofi, TB Alliance collaborate to accelerate new treatments for TB

Monday, September 24, 2012 08:00 AM

Global healthcare company Sanofi and the not-for-profit organization Global Alliance for TB Drug Development (TB Alliance) have formed a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB).

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

FDA approves new multiple sclerosis treatment Aubagio

Friday, September 14, 2012 12:48 PM

The FDA has approved Sanofi Aventis’ Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

More... »

Oncodesign, Sanofi ink research collaboration and license agreement

Friday, September 14, 2012 11:57 AM

Oncodesign, a French drug discovery company and oncology pharmacology service provider, has entered into a strategic research collaboration with global healthcare company Sanofi to apply Oncodesign's Nanocyclix technology to Sanofi kinase target programs.

More... »

Adventrx names Vetticaden as chief medical officer

Monday, August 20, 2012 04:01 PM

Adventrx Pharmaceuticals, a biopharmaceutical company based in San Diego, has appointed Santosh J. Vetticaden, M.D., Ph.D., as chief medical officer and senior vice president.

More... »

Astellas Pharma Europe appoints Wood as senior director, market access

Monday, August 20, 2012 03:21 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Dr, Susan Wood as senior director, market access.

More... »

Breast cancer drug market will be driven by 3 agents, says Decision Resources

Monday, August 20, 2012 02:18 PM

Three new breast cancer market entrants—Roche/Genentech’s Perjeta (pertuzumab) and trastuzumab-DM1 (T-DM1), and Novartis’s Afinitor (everolimus)—will drive growth in the breast cancer market through 2021, according to Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues.

More... »

FDA approves Zaltrap for metastatic colorectal cancer

Monday, August 6, 2012 12:51 PM

The FDA has approved Sanofi-Aventis’ Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

More... »

Sanofi launches Collaborate Activate Innovation Challenge

Wednesday, July 25, 2012 10:22 AM

Sanofi US has launched the Collaborate Activate Innovation Challenge, which will award a total of $500,000 to teams of patient advocacy groups or medical professional associations who deliver novel approaches to better engage patients in their own health.

More... »

Sanofi in research collaboration with BWH for type 1 diabetes

Thursday, July 19, 2012 02:23 PM

Sanofi has announced a new research collaboration with Boston’s Brigham and Women's Hospital (BWH), a teaching and research affiliate of Harvard Medical School, focused on immunology of type 1 diabetes. The two organizations will share knowledge and apply their respective expertise in basic and applied research regarding diabetes and drug target and candidate development.

More... »